Cholesterol levels in blood and the risk of prostate cancer: A meta-analysis of 14 prospective studies - Abstract

BACKGROUND: As a neutral lipid and prominent component of the Western diet, cholesterol levels might be a risk factor for prostate cancer.

However, current evidence has been inconsistent. This meta-analysis aimed to evaluate the association between blood cholesterol levels and the risk of prostate cancer.

METHODS: An extensive search was performed in MEDLINE and EMBASE for prospective studies that have reported the association between total cholesterol (TC), high-density lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL) levels in blood and risk of prostate cancer. Random-effects models were used to summarize the study-specific results.

RESULTS: Fourteen studies were included in this meta-analysis. In the meta-analysis, the summarized risk ratios (RR) for the highest to lowest cholesterol levels were as follows: 1.05 [95% confidence interval (CI), 0.97-1.14; P = 0.21] for TC, 0.93 (95% CI, 0.80-1.10; P = 0.40) for HDL, and 1.17 (95% CI, 0.88-1.55; P = 0.51) for LDL. When restricting to high-grade prostate cancer, the pooled RR was 1.32 (95% CI, 0.93-1.87; P = 0.13) for TC. In dose-response analyses, a 1 mmol/L increment in blood TC, HDL, and LDL level conferred an RR of 1.01 (95% CI, 0.99-1.02; P = 0.38), 0.98 (95% CI, 0.91-1.07; P = 0.72), and 1.04 (95% CI, 0.98-1.10; P = 0.24), respectively.

CONCLUSION: In this meta-analysis of 14 large prospective studies, blood TC, HDL, and LDL levels were not associated with the risk of either overall prostate cancer or high-grade prostate cancer.

IMPACT: Our findings did not appear to support the hypothesis that hypercholesterolemia increases the risk of prostate cancer.

Written by:
YuPeng L, YuXue Z, PengFei L, Cheng C, YaShuang Z, DaPeng L, Chen D.   Are you the author?
Department of Epidemiology, School of Public Health, Harbin Medical University, Harbin, China; Department of Preventive Medicine, School of Public Health, Harbin Medical University, Harbin, China; Department of Medical Oncology, The third Affiliated Hospital, Harbin Medical University, Harbin, China; Laboratory Center, Heilongjiang Entry-Exit Inspection and Quarantine Bureau, Harbin, China; Department of Urology Oncology, The third Affiliated Hospital, Harbin Medical University, Harbin, China.  ;  

Reference: Cancer Epidemiol Biomarkers Prev. 2015 May 7. Epub ahead of print.
doi: 10.1158/1055-9965.EPI-14-1329


PubMed Abstract
PMID: 25953767

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe